Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Infections with HIV-1 group O are found in 1 to 3 % of persons living with HIV in Cameroon. The natural history and treatment response is not well understood. The natural resistance to non nucleoside reverse transcriptase inhibitors and their possible low sensitivity to protease inhibitors complicate the choice of an adequate treatment options.
This observational study is aimed at evaluating the antiretroviral treatment response of HIV-1 group O infected patients in comparison with HIV-1 group M infected patients. The proposed standardized follow-up will facilitate a better understanding of the natural history and treatment specificities to improve the patients management.
This is a non randomized study, open label, with standardized follow-up. A total of 171 patients
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | HIV-1 group O infected patients |
| |
| 2 | HIV-1 group M infected patients |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Treatment initiation for HIV-1 group O infected patients | Drug | The first line regimen is adapted according to the hemoglobin level and the AgHBs status :
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients with plasmatic HIV viral load bellow 60 copies / ml | 48 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients with plasmatic HIV viral load bellow 60 copies / ml | 24 and 96 weeks | |
| Early and late slope of viral load decrease | between weeks 2 and 12, and week 24 | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
HIV-1 infected patients coming for medical care in four treatment centers in Yaounde.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Central | Yaoundé | Cameroon | ||||
| Hôpital de la CNPS |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31063537 | Derived | Kouanfack C, Unal G, Schaeffer L, Kfutwah A, Aghokeng A, Mougnutou R, Tchemgui-Noumsi N, Alessandri-Gradt E, Delaporte E, Simon F, Vray M, Plantier JC; ANRS 12168 DynaMO Study. Comparative Immunovirological and Clinical Responses to Antiretroviral Therapy Between HIV-1 Group O and HIV-1 Group M Infected Patients. Clin Infect Dis. 2020 Mar 17;70(7):1471-1477. doi: 10.1093/cid/ciz371. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
Not provided
Not provided
Not provided
plasma and mononucleus cells
|
| Treatment initiation for HIV-1 group M infected patients | Drug | The first line regimen is adapted according to the hemoglobin level and the AgHBs status :
|
|
| Early and late slope of CD4 counts increase |
| between weeks 2 and 12, and week 24 |
| Proportion of patients with a stabilized CD4 counts gain over 50% | 96 weeks |
| Time to virological failure | Through out the trial |
| Resistance mutation profile when virological failure | Through out the trial |
| Clinical evaluation : proportion of adverse events, AIDS related events, deaths, morphologic modification | Through out the trial |
| Yaoundé |
| Cameroon |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |